Given that AMPK is commonly inhibited in various pathophysiological conditions such as obesity and diabetes, which are known risk factors for CRC, targeting AMPK could be a promising strategy for mitigating intestinal tumorigenesis. Here, PRKAA1 is linked to obesity due to melanocortin 4 receptor deficiency.